CPAP and survival in moderate-to-severe obstructive sleep apnoea syndrome and hypoxaemic COPD

• Autor(a) principal: Machado, M-C. L. [UNIFESP]
• Data de Publicação: 2010
• Outros Autores: Vollmer, W. M., Togeiro, Sonia Maria [UNIFESP], Bilderback, A. L., Oliveira, M-V. C. [UNIFESP], Leitão Filho, Fernando Sergio, Queiroga, F. [UNIFESP], Lorenzi-Filho, G., Krishinan, J. A.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: http://dx.doi.org/10.1183/09031936.00192008; http://repositorio.unifesp.br/handle/11600/32042
• topic: Chronic obstructive pulmonary disease; continuous positive airway pressure; long-term oxygen therapy; obstructive sleep apnoea syndrome; survival

Obstructive sleep apnoea syndrome (OSAS) often coexists in patients with chronic obstructive pulmonary disease (COPD). the present prospective cohort study tested the effect of OSAS treatment with continuous positive airway pressure (CPAP) on the survival of hypoxaemic COPD patients. It was hypothesised that CPAP treatment would be associated with higher survival in patients with moderate-to-severe OSAS and hypoxaemic COPD receiving long-term oxygen therapy (LTOT).Prospective study participants attended two outpatient advanced lung disease LTOT clinics in São Paulo, Brazil, between January 1996 and July 2006. of 603 hypoxaemic COPD patients receiving LTOT, 95 were diagnosed with moderate-to-severe OSAS. of this OSAS group, 61 (64%) patients accepted and were adherent to CPAP treatment, and 34 did not accept or were not adherent and were considered not treated.The 5-yr survival estimate was 71% (95% confidence interval 53-83%) and 26% (12-43%) in the CPAP-treated and nontreated groups, respectively (p<0.01). After adjusting for several confounders, patients treated with CPAP showed a significantly lower risk of death (hazard ratio of death versus nontreated 0.19 (0.08-0.48)).The present study found that CPAP treatment was associated with higher survival in patients with moderate-to-severe OSAS and hypoxaemic COPD receiving LTOT.